Loading company
Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for Nurix Therapeutics, Inc. and every other company we cover.
Try it first on NVDA, AAPL, META, NKE or CAKE, where it is open to everyone.
$15.47-0.8%Nov 13 close
Figures through August 31, 2026, from the 10-Q filed October 13, 2026
Nurix licenses rights to experimental cancer drugs and protein-degradation research to pharmaceutical companies, while developing its own cancer and immune-disease medicines.